User login
Key clinical point: Talazoparib shows antitumor response in heavily pretreated patients with metastatic, castration-resistant prostate cancer (CRPC) with alterations in DNA damage repair (DDR) genes.
Major finding: The median follow-up was 16.4 months. The confirmed objective response rate (ORR) was 29.8%. The ORR was 46% in patients with BRCA2 alterations and 50% in those with BRCA1 alterations. Grade 3-4 adverse event rate was 48%; anemia, thrombocytopenia, and neutropenia were most common.
Study details: A multicenter, phase 2 TALAPRO-1 trial of 127 heavily pretreated patients with metastatic, CRPC with alterations in DDR genes who received talazoparib; 104 patients had measurable soft tissue disease.
Disclosures: This study was funded by Pfizer. The authors received grants/funding, consulting fees, travel/accommodation expenses, and/or honoraria from and/or reported employment and/or stock ownership in companies. Dr. JS de Bono also reported patent ownership.
Source: de Bono JS et al. Lancet Oncol. 2021 Aug 10. doi: 10.1016/ S1470-2045(21)00376-4.
Key clinical point: Talazoparib shows antitumor response in heavily pretreated patients with metastatic, castration-resistant prostate cancer (CRPC) with alterations in DNA damage repair (DDR) genes.
Major finding: The median follow-up was 16.4 months. The confirmed objective response rate (ORR) was 29.8%. The ORR was 46% in patients with BRCA2 alterations and 50% in those with BRCA1 alterations. Grade 3-4 adverse event rate was 48%; anemia, thrombocytopenia, and neutropenia were most common.
Study details: A multicenter, phase 2 TALAPRO-1 trial of 127 heavily pretreated patients with metastatic, CRPC with alterations in DDR genes who received talazoparib; 104 patients had measurable soft tissue disease.
Disclosures: This study was funded by Pfizer. The authors received grants/funding, consulting fees, travel/accommodation expenses, and/or honoraria from and/or reported employment and/or stock ownership in companies. Dr. JS de Bono also reported patent ownership.
Source: de Bono JS et al. Lancet Oncol. 2021 Aug 10. doi: 10.1016/ S1470-2045(21)00376-4.
Key clinical point: Talazoparib shows antitumor response in heavily pretreated patients with metastatic, castration-resistant prostate cancer (CRPC) with alterations in DNA damage repair (DDR) genes.
Major finding: The median follow-up was 16.4 months. The confirmed objective response rate (ORR) was 29.8%. The ORR was 46% in patients with BRCA2 alterations and 50% in those with BRCA1 alterations. Grade 3-4 adverse event rate was 48%; anemia, thrombocytopenia, and neutropenia were most common.
Study details: A multicenter, phase 2 TALAPRO-1 trial of 127 heavily pretreated patients with metastatic, CRPC with alterations in DDR genes who received talazoparib; 104 patients had measurable soft tissue disease.
Disclosures: This study was funded by Pfizer. The authors received grants/funding, consulting fees, travel/accommodation expenses, and/or honoraria from and/or reported employment and/or stock ownership in companies. Dr. JS de Bono also reported patent ownership.
Source: de Bono JS et al. Lancet Oncol. 2021 Aug 10. doi: 10.1016/ S1470-2045(21)00376-4.